Pfizer (NYSE:PFE) Trading 2.1% Higher – Should You Buy?

Shares of Pfizer Inc. (NYSE:PFE) were up 2.1% during trading on Wednesday . The company traded as high as $24.82 and last traded at $24.7710. 44,094,280 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 42,613,000 shares. The stock had previously closed at $24.25.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received a fresh boost from news that PADCEV plus Keytruda won FDA approval for use in muscle-invasive bladder cancer, which supports the company’s oncology growth narrative. Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC
• Positive Sentiment: Several articles argued that Pfizer stock may be fairly valued or offer a potential buying opportunity, citing a relatively low valuation, dividend yield, and upside tied to pipeline execution and acquisitions. Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View
• Neutral Sentiment: Analysts noted Pfizer is trading below its 50-day and 200-day moving averages, reflecting a cautious technical setup as investors balance fading COVID-related revenue against longer-term pipeline growth. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
• Neutral Sentiment: Pfizer also suspended sales of Premarin vaginal cream in India because of supply challenges, a development that looks more like an operational hiccup than a major earnings driver. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma escalated patent litigation against Pfizer and BioNTech, filing international lawsuits over lipid nanoparticle technology and seeking damages and injunctions. That adds legal overhang and could raise long-term costs or uncertainty for Pfizer. ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Citigroup lifted their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Guggenheim cut their price target on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Monday. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Stock Up 1.3%

The business’s 50 day moving average is $25.22 and its 200-day moving average is $26.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market capitalization of $143.24 billion, a price-to-earnings ratio of 19.19 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 EPS. The business’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Hennessy Advisors Inc. grew its stake in shares of Pfizer by 27.0% in the second quarter. Hennessy Advisors Inc. now owns 296,113 shares of the biopharmaceutical company’s stock worth $7,130,000 after acquiring an additional 63,013 shares during the last quarter. Berman McAleer LLC increased its position in Pfizer by 9.2% during the second quarter. Berman McAleer LLC now owns 10,522 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 887 shares during the period. Northeast Investment Management raised its stake in Pfizer by 1.6% during the 2nd quarter. Northeast Investment Management now owns 38,632 shares of the biopharmaceutical company’s stock valued at $930,000 after purchasing an additional 600 shares during the last quarter. Coastwise Capital Group LLC boosted its holdings in Pfizer by 5.4% in the 2nd quarter. Coastwise Capital Group LLC now owns 80,028 shares of the biopharmaceutical company’s stock valued at $1,927,000 after purchasing an additional 4,074 shares during the period. Finally, Riversedge Advisors LLC bought a new stake in Pfizer in the 2nd quarter valued at $270,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.